Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Methods and systems for diagnosis, prognosis and selection of treatment of leukemia

A technology for leukemia and prognosis, which is applied in the fields of disease diagnosis, biochemical equipment and methods, and the determination/examination of microorganisms, and can solve problems such as unexplainable

Inactive Publication Date: 2008-04-02
WYETH LLC
View PDF5 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the MDR phenotype cannot account for all cases of gemtuzumab resistance that have been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
  • Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
  • Methods and systems for diagnosis, prognosis and selection of treatment of leukemia

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0283] The above methods (including preparation of blood samples, assembly of class predictors, and construction and comparison of expression profiles) can be easily used to diagnose or monitor the development, progression or treatment of AML. This can be achieved by comparing the expression profile of one or more AML disease genes in the individual of interest with a reference expression profile of at least one AML disease gene. The reference expression profile may include an average expression profile or a group of individual expression profiles, each of which represents the expression of peripheral blood genes in a specific AML patient or disease-free human. The similarity between the expression profile of the individual of interest and the reference expression profile indicates the presence or absence of the AML disease state. In many embodiments, the disease genes used for AML diagnosis are selected from Table 7.

[0284] One or more AML disease genes selected from Table 7 ca...

example 1

[0297] Example 1. Clinical trials and data collection

[0298] experimental design

[0299] The AML patients (13 women and 23 men) were all white and had an average age of 45 years (in the range of 19-66 years). The inclusion criteria for AML patients include a 20% excess of blast cells in the bone marrow; morphological diagnosis of AML according to the FAB classification system; and flow cytometry that indicates a positive CD33+ status. Participation in clinical trials requires a consistent pathological diagnosis of AML by the on-site pathologist following the histological evaluation of bone marrow aspiration. A summary of the patient's cytogenetic characteristics is presented in Table 11.

[0300] Cytogenetic characteristics of PG consenting AML patients in Table 11.0903B1-206-US contributing to the baseline sample

[0301] Cytogenetic characteristics

PG agrees (n=36) ＊

Normal karyotype

12(33％)

Compound karyotype (>3 abnormalities)

6(1...

example 2

[0311] Example 2. Disease-related transcripts in AML PBMC

[0312] The scaled frequency normalization method was used to standardize 36 AML PBMC samples with the U133A transcription profiles of 20 MDS PBMC and 45 healthy volunteers PBMC. A total of 7879 transcripts in one or more patterns with a maximum frequency greater than or equal to 10 ppm (expressed as 1P, 1≥10 ppm) in the pattern are detected.

[0313] To identify AML-related transcripts, the average fold difference between AML and normal PBMC was calculated by dividing the average expression level in the AML profile by the average expression level in the normal profile. Student's t test (two samples, unequal variance) was used to evaluate the significance of expression differences between groups.

[0314] For unsupervised hierarchical clustering, 7879 transcripts satisfying the expression filter factor 1P, 1≥10ppm were used. The data was log-transformed, and the gene expression values ​​were median-centered, and the aver...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods, systems and equipment for the prognosis, diagnosis and selection of treatment of AML or other types of leukemia. Genes prognostic of clinical outcome of leukemia patients can be identified according to the present invention. Leukemia disease genes can also be identified according to the present invention. These genes are differentially expressed in PBMCs of AML patients relative to disease-free humans. These genes can be used for the diagnosis or monitoring the development, progression or treatment of AML.

Description

[0001] Cross reference of related applications [0002] This application claims the rights and interests of U.S. No. 60 / 653,117 filed on February 16, 2005. Technical field [0003] The present invention relates to leukemia diagnostic genes and prognostic genes, and methods for using the diagnostic genes and prognostic genes in the diagnosis, prognosis and treatment selection of AML or other types of leukemia. Background technique [0004] Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by the excessive proliferation of immature leukemia blasts in the bone marrow. Approximately 90% of all AML cases show CD33 + The proliferation of mother cells, and CD33 is a cell surface antigen, which seems to be specifically expressed in myeloblasts and myeloid progenitor cells, but not in normal hematopoietic stem cells. Gemtuzumab ozogamicin (Mylotarg_ or GO) is an anti-CD33 antibody conjugated with calicheamicin, which is specifically designed to target CD33 in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/50C12Q1/68
CPCG01N33/57426G01N2800/52C12Q1/6837C12Q1/6886
Inventor 迈克尔·E·布尔奇斯基弗雷德里克·伊默曼纳塔莉·C·特温珍妮弗·安·斯托弗安德鲁·J·多尔纳
Owner WYETH LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com